lobbying_activities: 3338431

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3338431	a2932449-d86b-4bf4-8b97-72e156da7087	Q1	ASSOCIATION FOR ACCESSIBLE MEDICINES	16032	ASSOCIATION FOR ACCESSIBLE MEDICINES	2025	first_quarter	PHA	Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		650000	0	0	2025-04-16T18:37:15-04:00